Verici Dx (LSE:VRCI), a precision diagnostics company focused on organ transplant, has received clinical laboratory certification from the New York State Department of Health, completing its authorisation to provide testing services across all 50 US states and the District of Columbia.
New York's Clinical Laboratory Evaluation Program is considered the most stringent laboratory accreditation process in the country, and the approval simultaneously extends state-level clearance for Tutivia, Verici's blood-based test that generates a risk score classifying kidney transplant recipients as low or high risk of acute rejection.
New York performed more than 2,000 kidney transplants in 2025, making it one of the busiest transplant markets in the US and a clinically significant addition to the test's addressable footprint.
"Receiving certification and test approval from the NYSDOH not only expands access to Tutivia for transplant centres in the state but also provides independent validation of our laboratory and data science operations and clinical performance," said Sara Barrington, Chief Executive Officer.
Tutivia is designed to provide clinicians with an early, proactive indicator of rejection risk ahead of clinical injury, with the company positioning it against single-parameter tools such as cell-free DNA that measure downstream damage after it has occurred.
